RxDoctor Payments Data

Michael Rowland, MD

Family Medicine · Glasgow, VANPI 1992791081

Payments from drug & device makers

$1,062in general payments, 2019–2025

Across 46 payments — averaging $23.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$248
  • AbbVie$176
  • Pfizer$122
  • Otsuka America Pharmaceutical, Inc.$105
  • Novo Nordisk$86
  • Lilly USA, LLC$68
  • plus $257 from 8 others

What the payments were for

  • Food & beverage$1,062100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,062 in reported general payments places this provider in the 65th percentile of 2,553 family medicine providers in Virginia.

See all family medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$8,783
Medicare patients
151
Services billed
236

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban95$94,316
OzempicSemaglutide44$41,647
RybelsusSemaglutide16$20,505
JardianceEmpagliflozin14$16,773
MounjaroTirzepatide13$14,107
XareltoRivaroxaban12$9,899
VascepaIcosapent Ethyl12$6,855
Breo ElliptaFluticasone/Vilanterol14$6,738
Spiriva HandihalerTiotropium Bromide13$6,614
Fluticasone-SalmeterolFluticasone Propion/Salmeterol41$6,111
Lantus SolostarInsulin Glargine,hum.Rec.Anlog25$3,836
Albuterol Sulfate HfaAlbuterol Sulfate216$3,443
Metoprolol Succinate203$2,821
Atorvastatin Calcium275$2,304
Potassium Chloride58$1,997

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$122$94,31695 claims
Novo NordiskOzempic, Rybelsus$86$62,15260 claims
Lilly USA, LLCMounjaro$68$14,10713 claims
GSKBreo Ellipta$47$6,73814 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,553 family medicine providers in Virginia.

Other family medicine in Glasgow

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →